Title :

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study

Author(s) :

Beldi-Ferchiou, Asma [Auteur]
Hôpital Henri Mondor
Jais, Jean-Philippe [Auteur]
Département de Biostatistiques [Paris]
Ghesquieres, Herve [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Casasnovas, Rene Olivier [Auteur]
Lipides - Nutrition - Cancer [Dijon - U1231] [LNC]
Tilly, Hervé [Auteur]
Groupe d'étude des proliférations lymphoïdes [GPL]
Fruchart, Christophe [Auteur]
Institut d'Hématologie de Basse-Normandie [IHBN]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Haioun, Corinne [Auteur]
Hôpital Henri Mondor
Lazarovici, Julien [Auteur]
Institut Gustave Roussy [IGR]
Perrot, Aurore [Auteur]
Service d'Hématologie [CHRU Nancy]
Nicolas-Virelizier, Emmanuelle [Auteur]
Centre Léon Bérard [Lyon]
Salles, Gilles [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Godard, Nathalie [Auteur]
Hôpital Henri Mondor
Zamali, Imen [Auteur]
Hôpital Henri Mondor
Schiano De Colella, Jean-Marc [Auteur]
Institut Paoli-Calmettes [IPC]
Claudel, Alexis [Auteur]
Hôpital Henri Mondor
Corront, Bernadette [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Oberic, Lucie [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Briere, Josette [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Gaulard, Philippe [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
Hôpital Henri Mondor
Thieblemont, Catherine [Auteur]
Université Paris Cité [UPCité]
Delfau-Larue, Marie-Hélène [Auteur]
Hôpital Henri Mondor

Journal title :

British Journal of Haematology

Abbreviated title :

Br J Haematol

Volume number :

201

Pages :

256-266

Publisher :

Wiley

Publication date :

2023-02-06

ISSN :

1365-2141

English keyword(s) :

DLBCL
elderly
lenalidomide
NK cells
prognosis

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS ...
Show more >Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS in rituximab–chemotherapy responders. We conducted a REMARC ancillary study analysing the impact of lenalidomide maintenance on the prognostic value of low NKCCs. Blood samples from 335 elderly French patients enrolled in the REMARC trial were analysed by flow cytometry to obtain NKCCs at diagnosis (n = 220), at randomization (n = 186) and/or six months after randomization (n = 184). Baseline NKCCs < 100 cells/μl were associated with shorter PFS and OS (HRs = [2.2 (1.4, 3.3), p < 0.001] and [2.8 (1.7, 4.5), p < 0.001], respectively), independently of aaIPI. In a competing risk analysis, low NKCCs at baseline were associated with a higher risk of relapse/progression (p = 0.0025), but not of death without progression (p = 0.33). Lenalidomide did not affect the prognosis value of low baseline NKCCs (p = 0.6349). Similar results were obtained for low NKCCs at randomization. Our results demonstrate that low NKCCs at baseline and post rituximab–chemotherapy are robust prognostic factors in DLBCL and reveal that lenalidomide has no impact on this parameter. Other therapeutic strategies aiming at improving NK-cell function could improve outcomes in DLBCL.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Modélisation biopharmaceutique et pharmacocinétique

Submission date :

2023-05-25T02:17:06Z
2023-10-02T11:02:57Z